Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Boosted by TFB Advisors LLC

TFB Advisors LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,397 shares of the biopharmaceutical company’s stock after acquiring an additional 116 shares during the period. TFB Advisors LLC’s holdings in Gilead Sciences were worth $788,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in GILD. Vanguard Group Inc. lifted its position in Gilead Sciences by 2.6% in the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after purchasing an additional 2,910,147 shares during the period. Capital World Investors lifted its holdings in shares of Gilead Sciences by 1.4% in the first quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock valued at $6,189,435,000 after buying an additional 1,133,281 shares during the period. Capital Research Global Investors boosted its stake in Gilead Sciences by 2.7% during the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after buying an additional 1,589,240 shares in the last quarter. Legal & General Group Plc grew its holdings in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Gilead Sciences by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock worth $714,421,000 after acquiring an additional 268,208 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,437 shares of company stock worth $5,374,825 over the last 90 days. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Up 6.8 %

Gilead Sciences stock opened at $97.90 on Friday. The company has a market capitalization of $121.88 billion, a P/E ratio of 119.39, a P/E/G ratio of 3.13 and a beta of 0.17. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.32. The firm’s fifty day simple moving average is $84.58 and its 200-day simple moving average is $74.67. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GILD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Oppenheimer increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Piper Sandler boosted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.05.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.